Skip to main content
SpringerLink
Log in

Chemotherapie beim Pankreaskarzinom

  • Chapter
Hepatobiliäre und Pankreastumoren

  • 1430 Accesses

Zusammenfassung

Der Nutzen einer adjuvanten Therapie des mit kurativer Intention resezierten Pankreaskarzinoms wurde in den letzten Jahren eingehend erforscht. In Anbetracht der Aggressivität der Tumorentität und der hohen Rezidivraten auch nach R0-Resektionen (ca. 80% innerhalb von 5 Jahren, Sener et al. 1999) ist eine Ergänzung der operativen Verfahren im Sinne einer systemischen Behandlung logische Konsequenz und dringende Notwendigkeit zur Optimierung der Prognose der Patienten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 19.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Berz D, Miner T et al. (2007). »HER family inhibitors in pancreatic cancer: current status and future directions.« Expert Opin Ther Targets. 11(3): 337–47.

    Article  PubMed  CAS  Google Scholar 

  • Boeck S, Hinke A et al. (2007). »Importance of performance status for treatment outcome in advanced pancreatic cancer.« World J Gastroenterol. 13(2): 224–7.

    PubMed  Google Scholar 

  • Burris HA 3rd, Moore MJ et al. (1997). »Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.« J Clin Oncol. 15(6): 2403–13.

    PubMed  CAS  Google Scholar 

  • Chauffert B, Mornex F, et al. (2006). »Phase II trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by Gemcitabine vs. Gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study.« J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 24(No. 18S (June 20 Supplement), 2006): 4008.

    Google Scholar 

  • Cunningham D, et al. (2009). »Phase III randomised comparison of Gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.« J Clin Oncol 27(33): 5513–8

    Article  PubMed  CAS  Google Scholar 

  • Demols A, Peeters M et al. (2006). »Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study.« Br J Cancer. 94(4): 481–5.

    Article  PubMed  CAS  Google Scholar 

  • Dragovich T, Huberman M et al. (2006). »Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.« Cancer Chemother Pharmacol 6: 6.

    Google Scholar 

  • Heinemann V, Quietzsch D et al. (2006). »Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.« J Clin Oncol. 24(24): 3946–52.

    Article  PubMed  CAS  Google Scholar 

  • Hess V, Salzberg M, Borner M et al. (2003). “Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.« J Clin Oncol 21 (1): 66–8.

    Article  PubMed  CAS  Google Scholar 

  • Hettiarachchi RJ, Smorenburg SM et al. (1999). »Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread.« Thromb Haemost. 82(2): 947–52.

    PubMed  CAS  Google Scholar 

  • Icli F, Akbulut H et al. (2006). »Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer.« J Surg Oncol 27: 27.

    Google Scholar 

  • Kalser MH, Ellenberg SS (1985). »Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.« Arch Surg. 120(8): 899–903.

    PubMed  CAS  Google Scholar 

  • Klaassen DJ, MacIntyre JM et al. (1985). »Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study.« J Clin Oncol. 3(3): 373–8.

    PubMed  CAS  Google Scholar 

  • Klapdor R, Bahlo M et al. (2005). »Further evidence for prolongation of survival of pancreatic cancer patients by efficacy orientated sequential polychemotherapy (EOSPC) based on serial tumor marker determinations (CA 19–9/CEA).« Anticancer Res. 25(3A): 1687–91.

    PubMed  CAS  Google Scholar 

  • Kneifel B et al. (1998). “Oral dexamethasone for the amelioration of the gemcitabine-induced side effects asthenia, edema, and flulike symptoms.« Onkologie (21): 229–231.

    Article  Google Scholar 

  • Kondo S, Ueno H et al. (2006). »Gemcitabine monotherapy versus chemoradiotherapy using 5-FU in patients with locally advanced pancreatic cancer.« 2006 Gastrointestinal Cancers Symposium Abstract No 137.

    Google Scholar 

  • Kozuch P, Grossbard ML et al. (2001). »Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.« Oncologist. 6(6): 488–95.

    Article  PubMed  CAS  Google Scholar 

  • Louvet C, Hincke A, Labianca R, Heinemann V (2006). »Increased survival using platinum analog combined with gemcitabine as compared to gemciatbien single agent in advanced pancreatic cancer: Pooled analysis of tow randomised trials, the GERCOR/GISCAD Intergroup Study and a German multicenter Study.« J Clin Oncol 24, No. 18S: 4003.

    Google Scholar 

  • Louvet C, Labianca R et al. (2005). »Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.« J Clin Oncol. 23(15): 3509–16.

    Article  PubMed  CAS  Google Scholar 

  • Millela M, Gelibter A. et al. (2004). »Exploratory phase Ii study of celecoxib and infusional fluorouracil as second-line treatment for advanced pancreatic cancer and biliary tree cancerExploratory phase Ii study of celecoxib and infusional fluorouracil as secondline treatment for advanced pancreatic cancer and biliary tree cancers.« J Clin Oncol, 2004 ASCO Annual Meeting Proceedings Part. I, Vol 22, No 14S (June 20 Supplement): 2006: 4183.

    Google Scholar 

  • Mini E, Nobili S et al. (2006). »Cellular pharmacology of gemcitabine.« Ann Oncol. 17 Suppl 5: v7-v12.

    Article  PubMed  Google Scholar 

  • Moertel CG, Frytak S et al. (1981). »Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation +5-fluorouracil: The Gastrointestinal Tumor Study Group.« Cancer. 48(8): 1705–10.

    Article  PubMed  CAS  Google Scholar 

  • Moore MJ (2005). »Brief communication: a new combination in the treatment of advanced pancreatic cancer.« Semin Oncol. 32(6 Suppl 8): 5–6.

    Article  PubMed  Google Scholar 

  • Neoptolemos J P, Stocken DD et al. (2004). »A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.« N Engl J Med. 350(12): 1200–10.

    Article  PubMed  CAS  Google Scholar 

  • Oettle H, Arnold D et al. (2000). »Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.« Anticancer Drugs. 11(8): 635–8.

    Article  PubMed  CAS  Google Scholar 

  • Oettle H, Pelzer U, Stieler J et. al (2005). „Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003).“ J Clin Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4031

    Google Scholar 

  • Oettle H, Post S et al. (2007). »Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.« Jama. 297(3): 267–77.

    Article  PubMed  CAS  Google Scholar 

  • Pelzer U, et al. (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol (Meeting Abstracts), 26(15 suppl): p. 4508-.

    Google Scholar 

  • Plunkett W., Huang P et al. (1996). »Gemcitabine: preclinical pharmacology and mechanisms of action.« Semin Oncol. 23(5 Suppl 10): 3–15.

    PubMed  CAS  Google Scholar 

  • Rich T, Harris J et al. (2004). »Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98–12.« Am J Clin Oncol. 27(1): 51–6.

    Article  PubMed  CAS  Google Scholar 

  • Rickles FR, Edwards RL(1983). »Activation of blood coagulation in cancer: Trousseau’s syndrome revisited.« Blood. 62(1): 14–31.

    PubMed  CAS  Google Scholar 

  • Riess H, et al. (2009) A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 003 study. J Clin Oncol (Meeting Abstracts), 26(15 suppl): p. 4508-.

    Google Scholar 

  • Saif MW (2006). »Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006.« Jop. 7(4): 337–48.

    PubMed  Google Scholar 

  • Sener SF, Fremgen A et al. (1999). »Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database.« J Am Coll Surg. 189(1): 1–7.

    Article  PubMed  CAS  Google Scholar 

  • Shen VS, Pollak EW (1980). »Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?« South Med J. 73(7): 841–3.

    PubMed  CAS  Google Scholar 

  • Tsavaris N, Kosmas C et al. (2005). »Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.« Invest New Drugs. 23(4): 369–75.

    Article  PubMed  CAS  Google Scholar 

  • Yamamitsu S, Kimura H et al. (2006). »Long-term repeatable chemotherapy for patients with advanced pancreatic cancer.« Gan To Kagaku Ryoho. 33 Suppl 1: 213–8.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CharitéCentrum für Tumormedizin/Med. Klinik m. S. Hämatologie und Onkologie, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin

    PD Dr. H. Oettle & Dr. med. M. Sinn

Authors
  1. PD Dr. H. Oettle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. med. M. Sinn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Oettle, H., Sinn, M. (2010). Chemotherapie beim Pankreaskarzinom. In: Hepatobiliäre und Pankreastumoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-04935-4_39

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-04935-4_39

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-04934-7

  • Online ISBN: 978-3-642-04935-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation